This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. VIRI, WHWK, PYRGF, OSTX, ATNM, EGRX, ELYM, NBRV, AADI, and NNVCShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Eagle Pharmaceuticals (EGRX), Eliem Therapeutics (ELYM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), and NanoViricides (NNVC). resTORbio vs. Its Competitors Virios Therapeutics Whitehawk Therapeutics PyroGenesis Canada OS Therapies Actinium Pharmaceuticals Eagle Pharmaceuticals Eliem Therapeutics Nabriva Therapeutics Aadi Bioscience NanoViricides resTORbio (NASDAQ:TORC) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Which has more risk and volatility, TORC or VIRI? resTORbio has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Does the media prefer TORC or VIRI? In the previous week, resTORbio's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score. Company Overall Sentiment resTORbio Neutral Virios Therapeutics Neutral Is TORC or VIRI more profitable? resTORbio's return on equity of -78.12% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets resTORbioN/A -78.12% -71.63% Virios Therapeutics N/A -130.33%-115.00% Do analysts rate TORC or VIRI? Virios Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 2.77%. Given Virios Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Virios Therapeutics is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals and insiders have more ownership in TORC or VIRI? 46.2% of resTORbio shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable valuation and earnings, TORC or VIRI? Virios Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioresTORbioN/AN/A-$82.74M-$2.41-0.29Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.02 SummaryresTORbio and Virios Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.05M$785.29M$5.48B$9.57BDividend YieldN/A4.84%4.00%4.18%P/E Ratio-0.381.2929.8825.14Price / SalesN/A25.43440.45103.02Price / CashN/A19.5635.9458.58Price / Book0.316.578.105.59Net Income-$82.74M-$3.92M$3.26B$265.48M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.69-2.0%N/A-47.3%$25.05MN/A-0.38N/AGap DownVIRIVirios TherapeuticsN/A$4.82+1.0%$5.00+3.7%+2,497.4%$92.82MN/A-17.855WHWKWhitehawk TherapeuticsN/A$1.77-2.2%N/AN/A$85.27M$27.78M11.0640News CoverageEarnings ReportPYRGFPyroGenesis Canada0.3491 of 5 stars$0.29+0.7%N/A-47.6%$54.23M$9.14M-4.8390High Trading VolumeOSTXOS Therapies2.2095 of 5 stars$1.83+1.7%$18.00+883.6%-47.8%$51.42MN/A-2.13N/AAnalyst ForecastATNMActinium Pharmaceuticals2.0777 of 5 stars$1.61-6.4%$4.00+148.4%-25.2%$50.23MN/A-1.1630Positive NewsEGRXEagle Pharmaceuticals1.9749 of 5 stars$3.69flatN/A-24.9%$47.92M$257.55M0.00100Gap DownELYMEliem TherapeuticsN/A$1.60+10.3%N/A-71.9%$47.60MN/A-3.029Gap UpNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi Bioscience0.4667 of 5 stars$1.81-7.2%$1.67-7.9%+33.3%$44.70M$25.07M-0.7940NNVCNanoViricides0.25 of 5 stars$1.70flatN/A-19.4%$27.32MN/A-2.3620 Related Companies and Tools Related Companies Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives PyroGenesis Canada Alternatives OS Therapies Alternatives Actinium Pharmaceuticals Alternatives Eagle Pharmaceuticals Alternatives Eliem Therapeutics Alternatives Nabriva Therapeutics Alternatives Aadi Bioscience Alternatives NanoViricides Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
